Anika Therapeutics (ANIK) Capital Expenditures (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Capital Expenditures data on file, last reported at $55000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 89.04% year-over-year to $55000.0 in Q1 2026; TTM through Mar 2026 was $6.4 million, a 1129.09% increase from a year earlier, with the FY2025 full-year figure at $6.8 million, up 968.23% from the prior year.
• Capital Expenditures for Q1 2026 stood at $55000.0, down from $6.8 million in the prior quarter.
• Over the last five years, Capital Expenditures for ANIK reached as high as $7.4 million in Q4 2022 and fell as low as -$5.1 million in Q3 2024.
• Historically, Capital Expenditures has averaged $1.2 million across 5 years, with a median of $622000.0 in 2024.
• Across the five-year window, Capital Expenditures plunged 244.4% in 2024 and surged 1203.26% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $7.4 million in 2022, then tumbled by 75.06% to $1.8 million in 2023, then sank by 71.68% to $521000.0 in 2024, then jumped by 1203.26% to $6.8 million in 2025, then tumbled by 99.19% to $55000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $55000.0 in Q1 2026, $6.8 million in Q4 2025, and -$4.3 million in Q3 2025.